[go: up one dir, main page]

MX2009012272A - Vectores para la expresion de genes multiples. - Google Patents

Vectores para la expresion de genes multiples.

Info

Publication number
MX2009012272A
MX2009012272A MX2009012272A MX2009012272A MX2009012272A MX 2009012272 A MX2009012272 A MX 2009012272A MX 2009012272 A MX2009012272 A MX 2009012272A MX 2009012272 A MX2009012272 A MX 2009012272A MX 2009012272 A MX2009012272 A MX 2009012272A
Authority
MX
Mexico
Prior art keywords
nucleic acid
acid molecule
vectors
gene expression
multiple gene
Prior art date
Application number
MX2009012272A
Other languages
English (en)
Inventor
Nathalie Silvestre
Doris Schmitt
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of MX2009012272A publication Critical patent/MX2009012272A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención provee un vector para expresar por lo menos una primera y una segunda moléculas de ácido nucleico que exhiben un porcentaje de homología de aproximadamente 80% o más de 80% sobre una porción de 40 o más nucleótidos continuos, y en donde dicha primera molécula de ácido nucleico y/o dicha segunda molécula de ácido nucleico son modificadas para reducir dicho porcentaje de homología hasta menos de 75%; la presente invención se refiere también a moléculas de ácido nucleico sustancialmente aisladas que comprenden una secuencia de nucleótidos como se define en cualquiera de SEQ ID NO: 9-15 y 66-69; provee también una célula hospedera y una composición farmacéutica que comprenden dicha molécula de ácido nucleico o vector, así como su uso para propósitos terapéuticos o preventivos.
MX2009012272A 2007-05-15 2008-01-29 Vectores para la expresion de genes multiples. MX2009012272A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07360019 2007-05-15
PCT/EP2008/051031 WO2008138648A1 (en) 2007-05-15 2008-01-29 Vectors for multiple gene expression

Publications (1)

Publication Number Publication Date
MX2009012272A true MX2009012272A (es) 2009-12-01

Family

ID=39522406

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012272A MX2009012272A (es) 2007-05-15 2008-01-29 Vectores para la expresion de genes multiples.

Country Status (16)

Country Link
US (1) US8337859B2 (es)
EP (1) EP2162544B1 (es)
JP (1) JP5474767B2 (es)
KR (1) KR101514473B1 (es)
CN (1) CN101688223B (es)
AR (1) AR065075A1 (es)
AU (1) AU2008250520B2 (es)
BR (1) BRPI0810305A2 (es)
CA (1) CA2686772C (es)
ES (1) ES2416361T3 (es)
IL (1) IL201963A (es)
MX (1) MX2009012272A (es)
PE (1) PE20090483A1 (es)
RU (1) RU2462513C2 (es)
TW (1) TW200844231A (es)
WO (1) WO2008138648A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2160402A2 (en) 2007-05-15 2010-03-10 Transgene SA Signaling peptides
US9206440B2 (en) * 2009-01-23 2015-12-08 Roger Williams Hospital Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same
SG178254A1 (en) * 2009-08-07 2012-03-29 Transgene Sa Composition for treating hbv infection
EP2558116B2 (de) * 2010-04-16 2020-01-08 General Vectors GmbH Mittel zur lokalen behandlung von zervixdysplasien
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
AU2012245395A1 (en) * 2011-04-20 2013-11-14 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
IN2014DN06118A (es) * 2012-01-24 2015-08-14 Sanford Res Usd
EP2958994B1 (en) * 2013-02-21 2019-05-29 Turnstone Limited Partnership Vaccine composition
EP3207142A4 (en) * 2014-10-14 2018-07-04 The Trustees Of The University Of Pennsylvania Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
SG11201808809PA (en) * 2016-05-02 2018-11-29 Janssen Vaccine & Prevention B V Therapeutic hpv vaccine combinations
WO2018060288A1 (en) * 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
EP3461497A1 (en) 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
WO2020106924A1 (en) * 2018-11-21 2020-05-28 Mayo Foundation For Medical Education And Research Adenoviruses and methods for using adenoviruses
KR20240086779A (ko) * 2022-12-05 2024-06-19 경상국립대학교산학협력단 다중 단백질의 발현을 위한 신규 핵산 구조체

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
ATE285410T1 (de) 1997-06-30 2005-01-15 Nippon Kayaku Kk Naphthyridinderivate oder salze davon
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
FR2774699B1 (fr) * 1997-11-17 2003-10-03 Rhone Poulenc Rorer Sa Methode de reduction des evenements de recombinaison homologue
PT1212358E (pt) * 1999-08-25 2005-04-29 Merck & Co Inc Genes sinteticos de papilomavirus humano
US7001995B1 (en) * 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
WO2003018055A1 (en) 2001-08-23 2003-03-06 Merck & Co., Inc. Vaccine using papilloma virus e proteins delivered by viral vector
WO2003097845A1 (en) * 2002-05-16 2003-11-27 Bavarian Nordic A/S Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
PL2118292T3 (pl) * 2007-01-30 2011-12-30 Transgene Sa Polipeptyd E2 wirusa brodawczaka stosowany do szczepienia

Also Published As

Publication number Publication date
RU2009144898A (ru) 2011-06-20
KR20100019432A (ko) 2010-02-18
JP2010526547A (ja) 2010-08-05
EP2162544A1 (en) 2010-03-17
TW200844231A (en) 2008-11-16
JP5474767B2 (ja) 2014-04-16
CN101688223B (zh) 2013-07-31
IL201963A (en) 2013-09-30
US8337859B2 (en) 2012-12-25
AU2008250520A1 (en) 2008-11-20
ES2416361T3 (es) 2013-07-31
BRPI0810305A2 (pt) 2018-07-10
RU2462513C2 (ru) 2012-09-27
IL201963A0 (en) 2011-08-01
PE20090483A1 (es) 2009-05-20
HK1135731A1 (en) 2010-06-11
US20100303838A1 (en) 2010-12-02
EP2162544B1 (en) 2013-04-17
CA2686772C (en) 2015-03-24
AR065075A1 (es) 2009-05-13
KR101514473B1 (ko) 2015-04-22
AU2008250520B2 (en) 2013-10-31
WO2008138648A1 (en) 2008-11-20
CA2686772A1 (en) 2008-11-20
CN101688223A (zh) 2010-03-31

Similar Documents

Publication Publication Date Title
MX2009012272A (es) Vectores para la expresion de genes multiples.
MY156855A (en) Novel regulatory elements
MX2014001070A (es) Gen plaguicida axmi279 y sus metodos de uso.
MX2012000202A (es) Gen plaguicida axmi-205 y metodos para su uso.
BR112012020705A2 (pt) axmi221z, axmi222z, axmi224z, e axmi225z genes de delta-endotoxina e métodos para sua utilização.
MX2011003229A (es) Terapia genica con porfobilinogeno desaminasa.
MX363910B (es) Gen de la toxina axmi270 y sus metodos de uso.
NZ603901A (en) Vectors and sequences for the treatment of diseases
PH12015500549A1 (en) Hppd variants and methods of use
BRPI0806252B8 (pt) molécula de ácido nucléico de promotor, vetor recombinante, célula de hospedeiro e método de expressão de gene alvo
EA201170717A1 (ru) Дельта-эндотоксиновый ген axmi-150 и способы его применения
NZ603348A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
MX357562B (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas vip3a de bacillus thuringiensis y metodos para su uso.
MX354219B (es) Familia de genes plaguicidas axmi-192 y metodos para su uso.
EP3124614A3 (en) Lactococcus promoters and uses thereof
MX362999B (es) Gen de la delta-endotoxina axmi345 y sus metodos de uso.
MX351526B (es) Proteinas variantes axmi205 y sus metodos de uso.
MX2009000656A (es) Acidos nucleicos que se fijan a sdf-i.
EA201170685A1 (ru) Гены, кодирущие токсины нематод
GB201201178D0 (en) Novel enzymes
HK1198170A1 (en) Pseudomonas exotoxin a with less immunogenic b cell epitopes
NZ700902A (en) Lowering saturated fatty acid content of plant seeds
AU2012358181A8 (en) Compositions and methods for the delivery of biologically active RNAs
MX362455B (es) Gen de la toxina axmi335 de bacillus thuringiensis y sus metodos de uso.
NZ593893A (en) Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases

Legal Events

Date Code Title Description
FG Grant or registration